Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Stride 2013 Eur J Heart Fail"

From Bioblast
Β 
(5 intermediate revisions by 5 users not shown)
Line 1: Line 1:
{{Publication
{{Publication
|title=Stride N, Larsen S, Hey-Mogensen M, Sander K, Lund JT, Gustafsson F, Kober L, Dela F (2013) Decreased mitochondrial oxidative phosphorylation capacity in the human heart with left ventricular systolic dysfunction. Eur J Heart Fail 15: 150-157.
|title=Stride N, Larsen S, Hey-Mogensen M, Sander K, Lund JT, Gustafsson F, Kober L, Dela F (2013) Decreased mitochondrial oxidative phosphorylation capacity in the human heart with left ventricular systolic dysfunction. Eur J Heart Fail 15:150-7.
|info=[http://www.ncbi.nlm.nih.gov/pubmed/23115323 PMID: 23115323]
|info=[http://www.ncbi.nlm.nih.gov/pubmed/23115323 PMID: 23115323]
|authors=Stride N, Larsen S, Hey-Mogensen M, Sander K, Lund JT, Gustafsson F, Kober L, Dela F
|authors=Stride N, Larsen S, Hey-Mogensen M, Sander K, Lund JT, Gustafsson F, Kober L, Dela F
Line 11: Line 11:
''CONCLUSION'': Human LVSD is associated with markedly diminished OXPHOS capacity, particularly in MCFA oxidation. This offers a candidate mechanism for a compromised energetic state and decreased reliance on fatty acid utilization in HF.
''CONCLUSION'': Human LVSD is associated with markedly diminished OXPHOS capacity, particularly in MCFA oxidation. This offers a candidate mechanism for a compromised energetic state and decreased reliance on fatty acid utilization in HF.
|keywords=Heart failure,
|keywords=Heart failure,
|mipnetlab=DK Copenhagen Dela F,
|mipnetlab=DK Copenhagen Dela F, DK Copenhagen Larsen S
}}
}}
{{Labeling
{{Labeling
|instruments=Oxygraph-2k
|injuries=Mitochondrial disease
|injuries=Mitochondrial Disease; Degenerative Disease and Defect
|organism=Human
|organism=Human
|tissues=Cardiac muscle
|tissues=Heart
|preparations=Permeabilized tissue
|preparations=Permeabilized tissue
|couplingstates=OXPHOS, ETS
|enzymes=Complex I, Complex II;succinate dehydrogenase, Complex IV;cytochrome c oxidase
|substratestates=CI, CII, CIV, CI+II
|topics=Fatty acid
|enzymes=Complex I, Complex II; Succinate Dehydrogenase, Complex IV; Cytochrome c Oxidase
|couplingstates=OXPHOS, ET
|topics=Fatty Acid
|pathways=N, S, CIV, NS
|instruments=Oxygraph-2k
}}
}}

Latest revision as of 15:45, 5 March 2019

Publications in the MiPMap
Stride N, Larsen S, Hey-Mogensen M, Sander K, Lund JT, Gustafsson F, Kober L, Dela F (2013) Decreased mitochondrial oxidative phosphorylation capacity in the human heart with left ventricular systolic dysfunction. Eur J Heart Fail 15:150-7.

Β» PMID: 23115323

Stride N, Larsen S, Hey-Mogensen M, Sander K, Lund JT, Gustafsson F, Kober L, Dela F (2013) Eur J Heart Fail

Abstract: AIMS: Heart failure (HF) with left ventricular systolic dysfunction (LVSD) is associated with a shift in substrate utilization and a compromised energetic state. Whether these changes are connected with mitochondrial dysfunction is not known. We hypothesized that the cardiac phenotype in LVSD could be caused by reduced mitochondrial oxidative phosphorylation (OXPHOS) capacity and reduced mitochondrial creatine kinase (miCK) capacity. The study aim was to test mitochondrial OXPHOS capacity in LVSD myocardium compared with OXPHOS capacity in a comparable patient group without LVSD.

METHODS AND RESULTS: Myocardial biopsies were obtained from the left ventricle during cardiac valve or left ventricular assist device (LVAD) surgery. Patients were stratified according to left ventricular ejection fraction (LVEF) into LVSD (LVEF <45%, n = 14) or CONTROL (LVEF >45%, n = 15). Mitochondrial respiration was measured in muscle fibres with addition of non-fatty acid substrates or octanoyl-l-carnitine, a medium chain fatty acid (MCFA). The in situ enzyme capacity of miCK was determined from APD titrations in the presence or absence of creatine. Maximal OXPHOS capacity with non-fatty acid substrates was lower in the LVSD group compared with the CONTROL group (P ≀ 0.05). ADP sensitivity always increased significantly (P ≀ 0.05) with the addition of creatine, after which the sensitivity was highest (P ≀ 0.05) in LVSD compared with CONTROL. The stimulation of OXPHOS from octanoyl-l-carnitine titrations elicited ∼40% lower respiration in LVSD compared with CONTROL (P ≀ 0.05).

CONCLUSION: Human LVSD is associated with markedly diminished OXPHOS capacity, particularly in MCFA oxidation. This offers a candidate mechanism for a compromised energetic state and decreased reliance on fatty acid utilization in HF. β€’ Keywords: Heart failure

β€’ O2k-Network Lab: DK Copenhagen Dela F, DK Copenhagen Larsen S


Labels:

Stress:Mitochondrial disease  Organism: Human  Tissue;cell: Heart  Preparation: Permeabilized tissue  Enzyme: Complex I, Complex II;succinate dehydrogenase, Complex IV;cytochrome c oxidase  Regulation: Fatty acid  Coupling state: OXPHOS, ET  Pathway: N, S, CIV, NS  HRR: Oxygraph-2k